EUR/USD likely to find a peak near 1.25: UBS
Clifford Sosin, a ten percent owner of Cardlytics, Inc. (NASDAQ:CDLX), has sold 400,000 shares of the company’s common stock for approximately $452,760. The sales occurred in two separate transactions on August 18 and August 19, 2025. The stock, currently trading at $1.10, has declined over 70% year-to-date, according to InvestingPro data, which shows the company’s market capitalization has dropped to approximately $59 million.
On August 18, Sosin sold 200,000 shares at a price of $1.1411 per share. The following day, August 19, another 200,000 shares were sold at $1.1227 per share. Following these transactions, Sosin continues to indirectly hold 5,199,023 shares of Cardlytics. The company currently operates with a significant debt burden, with a debt-to-equity ratio of 3.75x, as reported by InvestingPro.
Sosin also indirectly holds $21,243,000 in 4.25% Convertible Senior Notes due 2029, which are convertible into 1,178,856 shares of Cardlytics common stock. With an overall Financial Health score rated as "WEAK" by InvestingPro, investors can access comprehensive analysis and 13 additional ProTips about Cardlytics through the platform’s detailed research reports.
In other recent news, Cardlytics Inc . reported its second-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of -$0.13 compared to the anticipated -$0.39. However, the company experienced a revenue shortfall, reporting $63.2 million against a forecasted $64.06 million. This revenue miss has raised concerns among investors despite the positive EPS outcome. Analysts had anticipated slightly higher revenue figures, and the discrepancy may have contributed to cautious investor sentiment. No significant mergers or acquisitions were announced in this period. Additionally, there were no recent analyst upgrades or downgrades reported for Cardlytics. The company’s financial performance continues to be closely monitored by stakeholders, given the mixed results. These developments reflect ongoing challenges and opportunities faced by Cardlytics in the current market environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.